Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide

Purpose Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with many causes, including Kawasaki disease (KD). The purpose of this study was to identify the laboratory tests needed to easily differentiate KD with HLH from incomplete KD alone. Methods We performed a retrospective study on patients diagnosed with incomplete KD and incomplete KD with HLH (HLH-KD) between January 2012 and March 2015. We compared 8 secondary HLH patients who were first diagnosed with incomplete KD with all 247 incomplete KD diagnosed patients during the study period. The complete blood count, erythrocyte sedimentation rate, platelet count, and serum total protein, albumin, triglyceride, C-reactive protein, N-terminal pro-brain natriuretic peptide (NT-proBNP), and ferritin levels were compared. Clinical characteristics and echocardiography findings were also compared between the 2 groups. Results The total duration of fever was longer in the HLH-KD group than in the KD group. White blood cell and platelet counts were higher in the KD group. Alanine aminotransferase, ferritin, and coronary artery diameter were increased in the HLH-KD group compared with those in the KD group. The median of NT-proBNP was significantly higher in the HLH-KD group than in the KD group at 889.0 (interquartile range [IQR], 384.5–1792.0) pg/mL vs. 233.0 (IQR, 107.0–544.0) pg/mL. Conclusion The NT-proBNP level may be helpful in distinguishing incomplete KD from KD with HLH. The NT-proBNP level should be determined in KD patients with prolonged fever, in addition to the white blood cell count, platelet count, and ferritin level, to evaluate secondary HLH.

[1]  B. McCrindle,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , 2017, Circulation.

[2]  Jin Hee Jung,et al.  N-terminal pro-brain natriuretic peptide can be an adjunctive diagnostic marker of hyper-acute phase of Kawasaki disease , 2016, European Journal of Pediatrics.

[3]  Yongmin Tang,et al.  Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. , 2016, Cytokine.

[4]  C. Wouters,et al.  Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities , 2016, British journal of haematology.

[5]  A. Killeen,et al.  Extreme Hyperferritinemia:  Causes and Impact on Diagnostic Reasoning. , 2016, American journal of clinical pathology.

[6]  Kuan-Ho Lin,et al.  Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis , 2015, BMJ Open.

[7]  S. Inoue,et al.  Forme Fruste of HLH (haemophagocytic lymphohistiocytosis): diagnostic and therapeutic challenges , 2015, BMJ Case Reports.

[8]  Y. Hong,et al.  Clinical characteristics and serum N-terminal pro-brain natriuretic peptide as a diagnostic marker of Kawasaki disease in infants younger than 3 months of age , 2014, Korean journal of pediatrics.

[9]  P. Pal,et al.  Macrophage activation syndrome in Kawasaki disease. , 2014, Indian pediatrics.

[10]  Ji Yoon Kim,et al.  Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease , 2013, Blood research.

[11]  G. Schiller,et al.  Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. , 2012, Clinical advances in hematology & oncology : H&O.

[12]  J. Carcillo,et al.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? , 2012, Critical Care.

[13]  A. Ganser,et al.  Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection , 2011, Critical care.

[14]  A. Ramanan,et al.  Review of haemophagocytic lymphohistiocytosis , 2010, Archives of Disease in Childhood.

[15]  S. Shang,et al.  HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AT INITIATION OF KAWASAKI DISEASE AND THEIR DIFFERENTIAL DIAGNOSIS , 2010, Pediatric hematology and oncology.

[16]  D. Haffner,et al.  Hemophagocytic lymphohistiocytosis and Kawasaki disease: Combined manifestation and differential diagnosis , 2009, Pediatric blood & cancer.

[17]  C. Balkan,et al.  An unusual cause of multiple organ dysfunction syndrome in the pediatric intensive care unit: Hemophagocytic lymphohistiocytosis , 2009, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[18]  N. Dahdah,et al.  Natriuretic Peptide as an Adjunctive Diagnostic Test in the Acute Phase of Kawasaki Disease , 2009, Pediatric Cardiology.

[19]  A. Filipovich Hemophagocytic lymphohistiocytosis (HLH) and related disorders. , 2009, Hematology. American Society of Hematology. Education Program.

[20]  P. Mccarthy,et al.  Kawasaki disease associated with reactive hemophagocytic lymphohistiocytosis. , 2008, The Pediatric infectious disease journal.

[21]  N. Rouphael,et al.  Infections associated with haemophagocytic syndrome , 2007, The Lancet Infectious Diseases.

[22]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[23]  S. Ohga,et al.  Histiocytic haemophagocytosis in a patient with Kawasaki disease: Changes in the hypercytokinaemic state , 1995, European Journal of Pediatrics.

[24]  E. Silverman,et al.  Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? , 2003, Pediatrics.

[25]  S. Kaplan,et al.  Hemophagocytic syndrome after Kawasaki disease. , 2003, The Pediatric Infectious Disease Journal.

[26]  M. Carcao,et al.  Adverse Outcomes in Primary Hemophagocytic Lymphohistiocytosis , 2002, Journal of pediatric hematology/oncology.

[27]  S. Sawhney,et al.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders , 2001, Archives of disease in childhood.

[28]  A. Al-Jefri,et al.  Hemophagocytosis complicating Kawasaki disease. , 2000, Pediatric hematology and oncology.

[29]  K. Obinata,et al.  Kawasaki disease followed by haemophagocytic syndrome , 1998, European Journal of Pediatrics.